A Complete Response Letter (CRL) from the FDA due to manufacturing issues can destroy a biotech. CEO Ron Cooper warns leaders to invest heavily in Chemistry, Manufacturing, and Controls (CMC) early, even when the cost exceeds the clinical trial spend. This early investment in professionalizing CMC is critical to de-risk the company's future.

Sana CEO Steve Harr actively questions whether the company's groundbreaking science can translate into a scalable, commercially viable therapy. This internal pressure focuses the team on solving not just the scientific challenges ("does it work?"), but also manufacturing ("can you scale it?") and the commercial model required for a true cure.

Vivtex's scientist-CEO successfully navigated the transition by hiring an experienced finance and operations lead early on. This freed him from learning non-R&D functions from scratch, allowing him to leverage his deep technical expertise for high-value activities like business development and scientific strategy.

Centana Growth uses its deep diligence process to uncover operational insights for founders. In one case, they collaboratively identified a flaw in a company's core matching algorithm during a diligence session, leading to immediate improvements before the deal even closed. This reframes diligence as a value-add activity.

Unlike most biotechs that start with researchers, CRISPR prioritized hiring manufacturing and process development experts early. This 'backwards' approach was crucial for solving the challenge of scaling cell editing from lab to GMP, which they identified as a primary risk.

CEO Marc Salzberg clarifies that for their recombinant protein, the difficulty was not in the manufacturing itself but in designing the complex upstream process, purification, and analytics. This innovation became a core asset and "claim to fame," allowing them to transfer a well-defined process to a capable CDMO for scaling.

According to Novartis's CEO, a top reason for rejecting potential biotech partners is their underinvestment in Chemistry, Manufacturing, and Controls (CMC). Startups often neglect this unglamorous work, leading to deal failure because the acquirer can't be sure the drug can be scaled efficiently and safely.

Trae Stephens argues his day-to-day operator role at Andrel provides an "incredible perspective" on the tooling modern tech companies actually need. This direct exposure offers a tremendous advantage for sourcing and diligencing relevant investments—an edge that purely financial investors lack.

When Vivtex's scientific founder became CEO, his most critical move was hiring an experienced finance and operations leader. This structure allows the CEO to leverage deep technical insight for strategic partnerships, while delegating operational complexities they are less equipped to handle.